RecBio and India’s Biological E company reached a product licensing cooperation on the recombinant nine-valent HPV vaccine
July 2, 2025
Source: drugdu
46
On June 30, RecBio announced that the company and Indian Biological ProductsBiological E (hereinafter referred to as "BE Company") signed a product licensing cooperation agreement for the recombinant nine-valent HPV vaccine REC603.
RecBio will transfer vaccine formulation and subpackaging technology to BE, and transfer stock solution production technology at an appropriate time. According to the agreement, BE is exclusively authorized to develop, produce and commercialize recombinant nine-valent HPV vaccines in India and the bidding market led by the United Nations Children's Fund (UNICEF) and the Pan American Health Organization (PAHO). At present,RecBio has received an advance payment for the cooperation and will receive milestone payments according to the progress of the cooperation, as well as royalties based on a certain percentage of annual net sales.
https://finance.eastmoney.com/a/202506303443960124.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Targeting tumor cell stemness may hold the key to treating colon cancer more effectively July 24, 2025
- Hypothyroidism Linked to Gut Microbiome Disturbances July 24, 2025
- GI Cancers On The Rise Among Younger Adults July 23, 2025
- FDA Elevates Dubai Chocolate Spread Recall to Class 1 Over Salmonella Risk July 23, 2025
- WuXi Biologics’ Five Manufacturing Sites Pass U.S. FDA Pre-approval Inspections; First Commercial Prefilled Syringe Filling Plant Approved July 23, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
